Alphamab Oncology reported that every agenda item tabled at the 12 June 2026 annual general meeting (AGM) was approved by poll, underscoring broad shareholder confidence in the company’s governance and strategic mandates.

The meeting covered seven ordinary resolutions. Shareholders holding 396.34 million votes—representing 100.00% of votes cast—adopted the audited consolidated financial statements and the reports of the directors and auditors for the year ended 31 December 2025.

Key authorisations included: • Share repurchase mandate: Up to 10% of issued shares (excluding treasury shares) received unanimous approval with 100.00% of votes cast in favour. • Issuance mandate: Directors were granted authority to allot, issue and deal in up to 20% of issued shares, backed by 95.44% support (378.26 million “for” vs. 18.08 million “against”). • Extension mandate: The share issue mandate extension linked to repurchased shares passed with identical 95.44% approval.

Board composition was reaffirmed. Executive Director Ms. Liu Yang was re-elected with 97.88% support, while independent non-executive directors Mr. Wu Dong, Ms. Wong Yan Ki Angel and Dr. Gao Xiang each secured at least 99.80% approval. Shareholders also authorised the Board to determine director remuneration (99.92% support) and re-appointed Deloitte Touche Tohmatsu as external auditor with 97.78% approval.

Capital structure as of the AGM totalled 974.38 million issued shares, including 5.88 million treasury shares that were excluded from voting. No shareholders were required to abstain, and Computershare Hong Kong Investor Services Limited acted as scrutineer.

All resolutions required—and received—simple majority approval, enabling Alphamab Oncology’s Board to proceed with its authorised buy-back and share-issuance plans, maintain its current director lineup and retain its auditor for the coming financial year.